Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More
Arrowhead Pharmaceuticals Secures Australian TGA Approval for Redemplo, Offering Hope for Familial Chylomicronemia Syndrome Patients
The Australian Therapeutic Goods Administration (TGA) has granted approval for Arrowhead Pharmaceuticals’ Redemplo (plozasiran), a novel therapeutic agent designed to…
Read More
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings – Pharmaceutical Technology
The European Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on three promising new drug candidates,…
Read More
